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Abstract
Background: Patients with end-stage renal disease (ESRD) have an impaired immune response with a prematurely
aged T-cell system. Mitogen-activated protein kinases (MAPKs) including extracellular signal-regulated kinase (ERK)
and p38, regulate diverse cellular programs by transferring extracellular signals into an intracellular response. T cell
receptor (TCR)-induced phosphorylation of ERK (pERK) may show an age-associated decline, which can be reversed
by inhibiting dual specific phosphatase (DUSP) 6, a cytoplasmic phosphatase with substrate specificity to dephosphorylate
pERK. The aim of this study was to assess whether ESRD affects TCR-mediated signaling and explore possibilities
for intervening in ESRD-associated defective T-cell mediated immunity.
Results: An age-associated decline in TCR-induced pERK-levels was observed in the different CD4+ (P < 0.05), but
not CD8+, T-cell subsets from healthy individuals (HI). Interestingly, pERK-levels of CD4+ T-cell subsets from young
ESRD patients were in between young and elderly HI. A differentiation-associated decline in TCR-induced ERK and
p38 phosphorylation was observed in T cells, although TCR-induced p38 phosphorylation was not significantly affected
by age and/or ESRD. Frequencies of TCR-induced CD69-expressing CD4+ T cells declined with age and were positively
associated with pERK. In addition, an age-associated tendency of increased expression of DUSP6 was observed in CD4+
T cells of HI and DUSP6 expression in young ESRD patients was similar to old HI. Inhibition of DUSP6 significantly
increased TCR-induced pERK-levels of CD4+ T cells in young and elderly ESRD patients, and elderly HI.
Conclusions: TCR-mediated phosphorylation of ERK is affected in young ESRD patients consistent with the
concept of premature immunological T cell ageing. Inhibition of DUSP6 specific for pERK might be a potential
intervention enhancing T-cell mediated immunity in ESRD patients.
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Background
ESRD patients have a defective T-cell mediated immune
system that is clinically characterized by an increased
risk of a variety of infections [1, 2] and impaired response
of vaccination [3–7]. Infections are the second leading
cause of mortality following cardiovascular disease and a
major cause of morbidity in ESRD patients [8].
Uremia-associated T-cell defects closely resemble pre-
mature immunological T-cell ageing [9]. ESRD patients
have a discrepancy of 15–20 years between the immuno-
logical T-cell age and their chronological age [10]. Declined
thymic output, more differentiated memory T cells, T cells
lacking co-stimulatory molecules like CD28, skewed T cell
receptor (TCR) Vβ repertoire diversity and shorter telo-
mere length are observed in ESRD patients compared to
age-matched healthy individuals (HI) [11].
TCR-induced signaling mediates clonal (positive or
negative) selection of thymocytes in the thymus and
initiates T cell immune responses in the periphery,
consisting of T cell proliferation and differentiation
[12]. The mitogen-activated protein kinase (MAPK)
pathway is one of the major pathways induced upon
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TCR stimulation [13]. Activation of MAPK is medi-
ated by phosphorylation of MAPK and downregulated
by MAPK phosphatase resulting in inactive MAPK
[14]. In particular, the extracellular signal-regulated
kinase (ERK) pathway is one of the important MAPK
pathways. Phosphorylation of ERK can reduce sensi-
tivity of cells to apoptosis and promote cell prolifera-
tion [15]. ERK activity controls the positive feedback
loop in the TCR-induced activation cascade and re-
duced ERK activity affects signal strength and activa-
tion of T cells [16, 17]. Reduced phosphorylation of
ERK is associated with decreased interleukin-2 (IL-2)
production [18] and vice versa [19]. Dual specific
phosphatases (DUSPs) represents a family of phospha-
tases that dephosphorylate phosphor-threonine and
phosphor-tyrosine residues on MAPK and that are
pivotal regulators of MAPK activities. DUSP6 is a
cytoplasmic phosphatase with substrate specificity to
dephosphorylate pERK [20]. Ageing is also associated
with defective signaling pathways [21, 22]. Recently it
was shown that decreased phosphorylation of ERK in
naive CD4+ T cells from elderly HI was associated
with more time to build up the required signaling
strength following stimulation compared to those
from young HI. This decreased phosphorylation of
ERK can be overcome by inhibiting DUSP6 [16].
P38 is another pivotal protein in the MAPK pathway
[23] and of interest with respect to age-related changes
is T cell activation. Most stimuli, including engagement
of TCR, costimulatory receptors, inflammation, stress,
growth factors, as well as DNA damage induce phos-
phorylation of p38 by various pathways [24, 25]. Al-
though phosphorylation of ERK and p38 from T cells
share some upstream molecules after triggering of TCR,
such as phosphorylation of CD3 zeta-chain associated
protein kinase of 70 kDa (ZAP70) [26], they each have
their unique upstream MAPK kinases (MKKs) [14].
Highly differentiated CD4+ T cells lacking expression of
CD28 are accumulated in elderly healthy individuals
[27], patients with ESRD [28], following chronic viral
infection [29], and also in patients suffering from auto-
immune disease [30]. Senescent CD27−CD28−CD4+ T cells
employ an MKK-independent mechanism for phosphory-
lating p38 and depend on 5′ adenosine monophosphate-
activated protein kinase (AMPK) and transforming growth
factor-β-activated protein kinase 1(TAK1)-binding protein
1(TAB1) ex vivo [31].
Little is known as to how MAPK signaling pathways in
ESRD patients. Understanding MAPK signaling in ESRD
patients may increase knowledge about mechanisms of
uremia-associated impaired T-cell mediated immunity
and offer possibilities for intervention. Here, we demon-
strate that TCR-induced phosphorylation of ERK, and
not p38, in CD4+ T cells decreases with age and T cell
differentiation. This pathway is specifically affected in
young ESRD patients and at the level of elderly healthy
individuals, compatible with the concept of premature
immunological T cell ageing in patients with renal fai-
lure. In addition, inhibition of DUSP6 may offer a po-
tential intervention for improving T-cell mediated
immunity in ESRD patients.
Methods
Study population
In line with our previous studies, young and elderly pa-
tients groups were defined based on their chronological
age [32, 33]. Twenty-four stable ESRD patients, defined
as having a glomerular filtration rate of ≤15ml/min with
or without renal replacement therapy (RRT; i.e. dialysis)
and 24 HI were included (Study population characteris-
tics are described in Table 1) at the outpatient clinic. Pa-
tients with any clinical or laboratory evidence of acute
bacterial or viral infection, malignancy, immunosuppres-
sive drug treatment within 28 days prior to transplantation
(except for glucocorticoids) were excluded. Lithium-
heparinized blood was drawn of ESRD patients and heal-
thy kidney donors. All individuals included gave informed
consent and the local medical ethical committee approved
the study (METC number: 2012–022). It was conducted
according to the principles of Declaration of Helsinki
and in compliance with International Conference on
Harmonization/Good Clinical Practice regulations.
Table 1 Clinical characteristics of the study population
HI ESRD patients P value
Number of individuals 24 24
Age groups (years; mean ± SD)
young 29,4 ± 5,6 34,6 ± 8,0 ns
elderly 70,5 ± 5,8 70,8 ± 4,2 ns
Sex (% male) 50 79,2 ns
CMV IgG serostatus (% pos) 62,5 62,5 ns
RRT (number; %) 11; (45,8%)
Duration of RRT in months
(median with range)
22 (1—37)
Hemodialysis (number) 7
Peritoneal dialysis (number) 4
Underlying kidney disease
(number; %)
atherosclerosis/hypertensive
nephropathy
8; (33%)
primary glomerulopathy 4; (17%)
Diabetic nephropathy 6; (25%)
congenital disorder 3; (13%)
others 2; (8%)
unknown 1; (4%)
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PBMCs preparation
Peripheral blood mononuclear cells (PBMCs) were iso-
lated from peripheral blood from HI and ESRD patients
as described previously [34] and then cryopreserved for
further analysis.
Phosphorylation-specific flow cytometry
PBMCs were stained with eFluor-450-labeled anti-CD7
(eBioscience, Vienna, Austria), allophycocyanin-Cy7 (APC-
Cy7)-labeled anti-CD8 (BD, Erembodegem, Belgium),
Brilliant Violet (BV)-510-labeled anti-CD16 (BD) and
fluorescein isothiocyanate (FITC)-labeled anti-CCR7 (R&D
system, Uithoorn, the Netherlands) for 30 min at room
temperature. Then 1 million PBMCs/50 μl were prepared
for stimulation by labeling cells with 20 μg/ml mouse anti-
human CD3 (BD) and mouse anti-human CD28 (BD) each
on ice for 20 min, followed by an incubation with goat-anti
mouse IgG (BD) for cross-linking on ice for 20 min. Sti-
mulation was initiated by transferring cells to a 37 °C water
bath for 10 min. Cells were fixed using Cytofix (BD) at
37 °C for 10 min and then permeabilized in 70% metha-
nol at -20 °C for 30 min. Subsequently, cells were
stained with peridinin chlorophyll (PerCP)-labeled anti-
CD4 (BD), phycoerythrin (PE)-Cy7-labeled anti-CD45RO
(BioLegend, Uithoorn, Netherlands), PE-labeled anti-
phospho-p38MAPK (pT180/pY182) (BD), and Alexa
Fluor (AF) 647-labeled anti-phospho-ERK1/2 (pThr202/
pTyr204) (BD). Phosphorylation was measured on a BD
FACSCanto II flow cytometer (BD) and data were ana-
lyzed by Kaluza™ software (Beckman Coulter, Woerden,
Netherlands). Median fluorescence intensity (MFI) of
phosphorylated ERK or p38, generated by Kaluza™, were
multiplied by 256 to make them comparable to the data
analyzed by FACS Diva software (linear value instead of
log-transformed value) (BD). The MFI obtained for anti-
CD3/anti-CD28-stimulation were corrected by subtracting
the MFI of the unstimulated condition.
CD69 and IL-2 measurement
PBMCs were either not or stimulated with anti-CD3/
anti-CD28 T-cell expander beads (Invitrogen Dynal,
Oslo, Norway) at different ratios, i.e. 1 cell / 0.1 bead, 1
cell / 0.5 bead, 1 cell / 1 bead for 6 h in human culture
medium (HCM; RPMI-1640 with GlutaMAX, 10% heat-
inactivated pooled human serum and 1% penicillin and
streptomycin) (Lonza, Breda, Netherlands) with Golgistop
(BD). Then cells were stained with AmCyan-labeled anti-
CD3 (BD), Pacific Blue-labeled anti-CD4 (BD), APC-
Cyanin 7 (APC-Cy7)-labeled anti-CD8 (BD), APC-labeled
anti-CD45RO (BD) and PE-Cy7-labeled anti-CCR7 (R&D
Systems) antibodies and a live–dead marker ViaProbe
(7-aminoactinomycin D; 7AAD; BD). Upon fixation
with FACS lysing solution (BD) and permeabilization
using FACS permeabilizing solution 2 (BD), cells were
stained intracellular using PE-labeled anti-CD69 (BD)
and FITC-labeled anti-IL-2 (BD). Percentages CD69-
expressing and IL-2 producing CD4+ T cell subsets
were evaluated upon measuring the samples on a BD
FACSCanto II flow cytometer (BD). Data were ana-
lyzed by Kaluza™ software (Beckman Coulter).
DUSP6/1 inhibition
PBMCs were pre-incubated in HCM including 50 μM
(E)-2-benzylidene-3-(cyclohexylamino)-2, 3-dihydro-1 H-
inden-1-one (BCI) (Merck – Millipore, Amsterdam,
Netherlands) at 37 °C for 1 h. BCI has been shown to be
an inhibitor of DUSP6 and DUSP1 activity. PBMCs were
subsequently washed 3 times and then stimulated by
CD3/CD28 antibodies (as described previously) for
10 mins and then MFI of pERK of BCI-pretreated T cells
was measured by Phosphorylation-specific flow cytometry
as described previously.
DUSP6/1 measurement
PBMCs were stained with AmCyan-labeled anti-CD3
(BD), Pacific Blue-labeled anti-CD4 (BD), APC-Cy7-
labeled anti-CD8 (Biolegend); APC-labeled anti-CD45RO
(BD) and PE-Cy7-labeled anti-CCR7 (R&D Systems) anti-
bodies and 7-AAD for 30 min at 4 °C. Upon fixation and
permeabilization using Fix/Perm buffer (eBioscience),
1% bovine serum albumin (Zwijndrecht, Netherlands)
was used to block Fc receptors. Then cells were further
stained with AF647-labeled anti-DUSP6 (Santa Cruz
Biotechnology, Heidelberg, Germany) and PE-labeled
anti-DUSP1 (Santa Cruz Biotechnology) for 30 min at
4 °C. MFI of DUSP6 and DUSP1 was measured on a
BD FACSCanto II flow cytometer (BD) and data were
analyzed using FACS Diva software version 6.1.2 (BD).
Statistical analyses
Data were analyzed by Graphpad Prism 6 (GraphPad
Software, CA, USA). Comparison between two groups
(non-parametric data) were using Mann Whitney test.
Comparison in multiple groups were using Friedman
test followed by Dunn’s Multiple Comparison T test or
repeated ANOVA test followed by Bonferroni’s multiple
comparison test. Comparison between DUSP6-treated
and non-treated conditions was done by Paired T- test.
All reported P-values are two-sided and were considered
statistically significant when P < 0.05.
Results
Study population
The demographic and clinical characteristics of the
study population are given in Table 1. Twelve patients
were within the young group (age 22–44 years) and 12
patients belonged to the elderly group (age 66–78 years).
Age- and cytomegalovirus (CMV)-matched HI, i.e. 13
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young (age 21–40 years) and 11 elderly (age 65–74 years)
HI were included for comparison. Approximately half of
the ESRD patients received RRT (dialysis) with a median
dialysis time of 22 months.
Decreased ERK phosphorylation in young ESRD patients
A typical flow cytometric example for analysis of ERK
phosphorylation is given in Fig. 1. First, we compared
phosphorylation of ERK and p38 between young and eld-
erly HI or young and elderly ESRD patients. A significant
age-related lower TCR-mediated phosphorylation of ERK
was observed within all CD4+ T cell subsets from HI (Fig.
2a–d). For example, the median of MFI value of CD4+
phosphorylated ERK (pERK) was 658 in young HI, which
was significantly higher than 535 in elderly HI (p = 0.015)
(Fig. 2a). This trend consistently existed between young
and elderly HI when we compared MFI value of pERK in
CD4+ naive (median 722 vs. 612, p = 0.022) (Fig. 2b), CM
(median 666 vs. 489, p = 0.021) (Fig. 2c) and EM subsets
(517 vs. 364, p = 0.018) (Fig. 2d). Due to the almost absent
EMRA subset within the CD4+ T cells, phosphorylation of
ERK and p38 within this subset was not evaluated.
However, no significant differences in expression levels
of pERK in total CD4+ T cells or the subsets were found
comparing young and elderly ESRD patients (Fig. 2a–c
&d). For example, the median (interquartile range)) MFI
value of CD4+ pERK in young patients was 613 (490–664)
and 541 (413–801) in elderly patients (p = 0.51). The me-
dian MFI value for CD4+ pERK in young patients was in
between the MFI values of young HI 658 (485–1212)) and
elderly HI (535 (305–620)) but did not significantly differ
from either group (respectively p = 0.13 and p = 0.06). This
age-associated decline in pERK was not found for CD8+ T
cell subsets (Fig. 2e–h & i). In addition, an age-related de-
cline in TCR-mediated phosphorylation of p38, was absent
in CD4+ T cells (Fig. 3a–c & d) as well as CD8+ T cells
(Fig. 3e–h & i) of both HI and ESRD patients. In con-
clusion, ESRD patients have a defective ERK, but not
p38, phosphorylation in CD4+ T cells, that is independ-
ent of age and at a level similar to aged HI.
Fig. 1 Typical example of the gating strategy for analysis of phosphorylation of ERK (pERK) in naive CD4+ T cell subsets. Briefly, (a) lymphocytes
were identified based on the forward/sideward characteristics followed by (b) the selection of CD7+ CD16− T cells. c These T cells were then
dissected into CD4+ and CD8+ T cells. d CCR7 and CD45RO were used to identify naive and different memory subsets within CD4+ T cells.
Furthermore, (e) pERK was measured in naive CD4+ T cells without and with CD3/CD28 stimulation, and median fluorescence intensities (MFI)
were shown (values multiplied by 256 in brackets). A similar gating strategy was employed for phosphorylation of ERK and p38 in all T cells subsets
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Phosphorylation of ERK is associated with T-cell
differentiation status
Next, we compared phosphorylation of ERK and p38
within different T cell subsets to assess whether
differentiation-associated effects exist in the study
groups. In all groups, a gradual decrease in TCR-
induced phosphorylation capacity was seen with increas-
ing CD4+ T cell differentiation. Phosphorylation of ERK
was highest in naive CD4+ T cells of young HI, followed
by that in the CM and EM subsets of the memory com-
partment (Fig. 4a). Median MFI dropped from 722 to
666 and 517 in the naive, CM and EM T cell subset, re-
spectively. Interestingly, in elderly HI as well as both
groups of ESRD patients (Fig. 4b, c & d), pERK levels
were still highest within naive CD4+ T cells compared to
the more differentiated EM T cell subset, but the differ-
ence with that observed within CM T cells disappeared.
ERK phosphorylation within CM is higher than that
within the EM compartment in young and elderly HI
(Fig. 4a & b), as well as in young patients (Fig. 4c),
but not in elderly patients (Fig. 4d). Differences for
the various CD8+ T-cell subsets with respect to TCR-
mediated phosphorylation of ERK between naive and
CM compartment, or between EM and EMRA were
less outspoken and not significantly different in HI
(Fig. 4e & f ) and patients (Fig. 4g & h). Similar to
ERK, phosphorylation of p38 showed a similar trend
to decrease with increasing differentiation status but
no significant decline in phosphorylation of p38 from
naive to CM in CD4+ in HI and patients (Fig. 5a–c &
d). In CD8+ T cells, p38 phosphorylation was de-
creased in highly differentiated EMRA compared to
CM in HI and patients (Fig. 5e–g & h). In conclu-
sion, a differentiation-associated decrease in anti-
CD3/CD28-induced phosphorylation of ERK and p38
in T cells was present in HI and patients.
Auto-phosphorylation (baseline) of ERK was associated
with ageing in HI and increased according to
differentiation status in CD4+ T cells
Baseline phosphorylation of ERK (i.e. auto-phosphorylation)
was significantly lower for total and naive CD4+T cells in
young HI compared with elderly HI, however, this
trend was not observed in patients (Fig. 6a & b).
Baseline levels of pERK were significantly lower in
the CD8+ memory compartment (CM, EM and
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Fig. 2 Phosphorylation of ERK in T cells subsets from healthy individuals (HI) and end stage renal disease (ESRD) patients. Phosphorylation of ERK
in (a) CD4+, (b) CD4+ naive, (c) CD4+ central memory (CM), (d) CD4+ effector memory (EM), as well as (e) CD8+, (f) CD8+ naive, (g) CD8+ CM, (h)
CD8+EM, (i) CD8+ highly differentiated effector T cells (EMRA). Dots and squares represent young (n = 13) and elderly HI (n = 11), and upward- and
downward-facing triangles correspond to young (n = 12) and elderly (n = 12) patients, respectively. P value: *< 0.05; Data are given as median with
interquartile range
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EMRA) when comparing young to elderly HI, but no
age-related differences were observed for patients
(Fig. 6g, h & i). Baseline phosphorylation of ERK was
lower in the naive CD4+ T cells when compared to
CM and/or EM in HI (Fig. 7 a & b) and patients
(Fig. 7c & d). Naive CD8+ T cells also had lower
baseline pERK when compared to EMRA in elderly
HI (Fig. 7f ), CM and EM in young patients (Fig. 7g),
and EM in elderly patients (Fig. 7h). Naive CD4+ T
cells had lower baseline phosphorylated p38 com-
pared to CM or EM in elderly HI (Additional file 1:
Fig. S1b), and lower p38 phosphorylation compared
to EM in young patients (Additional file 1: Figure
S1c). In CD8+ T cells, p38 auto-phosphorylation in
naive compartment was significantly lower than that
of EMRA in young and elderly HI (Additional file 1:
Figure S1e & f ), but this trend was not observed in
the patient population (Additional file 1: Figure S1 g
& h). To summarize, an age- as well as
differentiation-related increase in baseline levels of
pERK was observed for CD4+ T cells.
Neither CMV-serostatus nor RRT significantly influenced
ERK or p38 phosphorylation
CMV-seropositivity may promote immunological T-cell
ageing and was therefore analyzed for its association
with MAPK pathway activation. However, ERK or p38
phosphorylation within T cells showed no significant dif-
ference comparing CMV-seropositive individuals to their
CMV- seronegative counterparts in healthy individuals
and ESRD patients respectively (Additional file 1: Figure
S2 & S3). Moreover, in ESRD patients, ERK or p38 phos-
phorylation was not significantly different between the
patients receiving RRT (i.e. dialysis) and those without
RRT (Additional file 1: Fig. S4 & S5). In conclusion, nei-
ther CMV-serostatus nor RRT significantly influenced
TCR-stimulation induced phosphorylation of ERK or p38.
Age-related decline in anti-CD3/CD28-induced CD69-
expressing CD4+ T cells positively associated with
phosphorylation of ERK
A typical flow cytometric example for analysis of fre-
quencies of CD69-expressing and IL-2 producing CD4+
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Fig. 3 Phosphorylation of p38 in T cells subsets from healthy individuals (HI) and end stage renal disease (ESRD) patients. Phosphorylation of p38
in (a) CD4+, (b) CD4+ naive, (c) CD4+ central memory (CM), (d) CD4+ effector memory (EM), as well as (e) CD8+, (f) CD8+ naive, (g) CD8+ CM, (h)
CD8+EM, (i) CD8+ highly differentiated effector T cells (EMRA). Dots and squares represent young (n = 13) and elderly HI (n = 11), and upward- and
downward-facing triangles correspond to young (n = 12) and elderly (n = 12) patients, respectively. P value: *< 0.05; Data are given as median with
interquartile range
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Fig. 4 Phosphorylation of ERK according to T cell differentiation status in healthy individuals (HI) and end stage renal disease (ESRD) patients.
Phosphorylation of ERK in CD4+ T cells from (a) young HI (n = 13), (b) elderly HI (n = 11), (c) young patients (n = 12), and (d) elderly patients
(n = 12), as well as CD8+ T cells from (e) young HI, (f) elderly HI, (g) young patients, and (h) elderly patients. Dots, squares, upward- and
downward-facing triangles represent naive, central memory (CM), effector memory (EM) and highly differentiated effector T cells (EMRA) T cells,
respectively. P value: *< 0.05; **< 0.01; ***< 0.001; Data are given as median with interquartile range
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Fig. 5 Phosphorylation of p38 according to T cell differentiation status in healthy individuals (HI) and end stage renal disease (ESRD) patients.
Phosphorylation of ERK in CD4+ T cells from (a) young HI (n = 13), (b) elderly HI (n = 11), (c) young patients (n = 12), and (d) elderly patients
(n = 12), as well as CD8+ T cells from (e) young HI, (f) elderly HI, (g) young patients, and (h) elderly patients. Dots, squares, upward- and
downward-facing triangles represent naive, central memory (CM), effector memory (EM) and highly differentiated effector T cells (EMRA) T cells,
respectively. P value: *< 0.05; **< 0.01; ***< 0.001; Data are given as median with interquartile range
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T cells after CD3/CD28 stimulation was given in
Additional file 1: Figure S6. Higher frequencies of
CD69-expressing CD4+ T cells were observed in
young HI compared to that in elderly HI when stim-
ulated with different ratios of anti-CD3/CD28 beads
to cells (Fig. 8a). This age-related decline in CD69-
expressing cells was observed for naive CD4+ T cells
in the healthy population at a ratio of 1:0.1 (Fig. 8b)
and at 1:0.1 and 1:1 ratios for memory CD4+ T cells
(Fig. 8c). Percentages of IL-2 producing CD4+ T cells
did not reveal an age-associated decline in our study
population (Fig. 8d, e & f ). Percentages of CD69-
expressing CD4+ T cells following stimulation with
anti-CD3/CD28 beads (at ratios 1:0.5 and 1:1) were
associated with ERK phosphorylation, presented as
the fold increase in MFI dividing the MFI from stim-
ulated samples by that of unstimulated samples (Fig.
8g). Percentages of IL-2 producing CD4+ T cells
were not associated with pERK (Fig. 8h). In addition,
frequencies of CD69-expressing CD4+ T cells were
significantly higher in the naive subset compared to
CM or EM (Fig. 8i). In short, an age-related decline
in anti-CD3/CD28-induced percentages of CD69-
expressing CD4+ T cells was observed and percent-
ages of CD69-expressing CD4+ T cells were posi-
tively associated with phosphorylation of ERK.
BCI promoted TCR-mediated phosphorylation of ERK
BCI is known to inhibit DUSP6 but also decrease levels
of DUSP1 (product document, Merck – Millipore). BCI
did not significantly enhance phosphorylation of ERK
in young HI; in contrast, in elderly HI and both
young and elderly ESRD patients, the pERK level
was significantly upregulated in all CD4+ T cell sub-
sets pretreated with BCI compared to that without
(Fig. 9a–c & d). The average fold increase in pERK
levels in naive CD4+ T cell subsets were 3.8, 2.5, and
2.1 in elderly HI, young and elderly ESRD patients,
respectively. This was not observed for CD8+ T cells
(Additional file 1: Figure S7). In short, BCI promoted
TCR-mediated phosphorylation of ERK in CD4+ T
pERK in CD4+ T cells
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Fig. 6 Auto-phosphorylation (baseline) of ERK in T cells subsets from healthy individuals (HI) and end stage renal disease (ESRD) patients.
Phosphorylation of ERK in (a) CD4+, (b) CD4+ naive, (c) CD4+ central memory (CM), (d) CD4+ effector memory (EM), as well as (e) CD8+, (f) CD8+
naive, (g) CD8+ CM, (h) CD8+EM, (i) CD8+ highly differentiated effector T cells (EMRA). Dots and squares represent young (n = 13) and elderly HI
(n = 11), and upward- and downward-facing triangles correspond to young (n = 12) and elderly patients (n = 12), respectively. P value: *< 0.05;
Data are given as median with interquartile range
Huang et al. Immunity & Ageing  (2017) 14:14 Page 8 of 14
cells of both elderly HI as well as young and old
ESRD patients.
DUSP6 and DUSP1 expression in CD4+ T cells
In an attempt to unravel whether effects of BCI on
pERK levels were mediated by interfering with
DUSP6 and/or DUSP1, we measured DUSP6 and
DUSP1 levels within CD4+ T cells in a small fraction
of our study cohort. Due to limited availability of ma-
terials only 10 HI (4 young and 6 elderly) and 9
ESRD patients (4 young and 5 elderly) could be in-
cluded. A typical flow cytometric example for analysis
of DUSP6 and DUSP1 is given in Additional file 1:
Figure S8. An age-associated trend of increased levels
of DUSP6 was noted for total and naive CD4+ T cells
in HI (Fig. 10a & b). The opposite was present com-
paring young to old ESRD patients (Fig. 10a, b & c).
Levels of DUSP6 in young ESRD patients were simi-
lar to old HI. Like observed for pERK, a significant
differentiation-associated increase in DUSP6 levels
was observed (Fig. 10 d). Interestingly, DUSP1 ex-
pression in CD4+ T cells was quite comparable be-
tween both young and elderly HI and patients (Fig.
10e, f, & g). To conclude, an age-related tendency of
increased levels of DUSP6, but not DUSP1, was ob-
served for HI. Moreover, DUSP6 expression was sig-
nificantly associated with T-cell differentiation status
in CD4+ T cells.
Discussion
The main observation of this study was that TCR-
mediated phosphorylation of ERK in CD4+ T cells of
young patients was in between young and old HI. Phos-
phorylation of ERK decreased in highly differentiated T-
cell subsets compared to naive T cells. This defective
TCR-mediated phosphorylation was specific as it could
be restored by addition of a DUSP6 inhibitor. TCR-
induced p38 phosphorylation was comparable between
ESRD patients and HI.
Beyond midlife, the immune system shows age-related
features and its defensive capabilities becomes impaired
[35]. The uremia-associated inflammatory environment
present in ESRD patients accelerates this age-related im-
mune senescence process. In addition to declined thymic
output, accumulation of highly differentiated T cells,
short telomere length [10, 33, 36] and narrowed TCR-
Vβ repertoire diversity [32], this study indicates that
young ESRD patients also have a defective CD4+ TCR
activation judging from the reduced capacity to phos-
phorylate ERK upon TCR-triggering. ERK activity is crit-
ical for TCR threshold calibration, as it controls positive
feedback loops in TCR-induced activation [17]. Reduced
ERK activity impairs TCR signal strength and activation,
and favors T cells with higher affinity to antigen to be
activated, leading to a contracted immune response to a
given antigen [16]. The ERK phosphorylation upregula-
tion of early activation marker CD69 on T cells ensures
a proper inducing activation of T cells in the lymph node
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Fig. 7 Auto-phosphorylation (baseline) of ERK according to T cell differentiation status in healthy individuals (HI) and end stage renal disease
(ESRD) patients. Phosphorylation of ERK in CD4+ T cells from (a) young HI (n = 13), (b) elderly HI (n = 11), (c) young patients (n = 12), and (d)
elderly patients (n = 12), as well as CD8+ T cells from (e) young HI, (f) elderly HI, (g) young patients, and (h) elderly patients. Blank bars and bars
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respectively. P value: *< 0.05; **< 0.01; ***< 0.001; Data are given as median with interquartile range
Huang et al. Immunity & Ageing  (2017) 14:14 Page 9 of 14
[37], and also play an important role in T cell prolifera-
tion [38] and IL-2 production [39, 40]. In addition, ERK
activation impacts cellular apoptosis as it inhibits Fas-
mediated apoptosis in T cells [41]. Evaluating ERK phos-
phorylation is a valuable tool to study more upstream
molecules in the defective T-cell mediated immune sys-
tem from ESRD patients. T cells from rheumatoid arth-
ritis (RA) patients exhibit several defects which can also
be viewed as premature immunological ageing [42].
However, ERK phosphorylation in CD4+ T cells of RA
patients selectively increased [43]. This increased ERK
activation lowers the TCR threshold in T cells of RA pa-
tients to respond to self-antigens, which may partly ex-
plain the adaptive immune system of RA patients to
exhibit abnormalities that go beyond the local inflamma-
tory response in the synovium [44].
DUSP6 is a cytoplasmic phosphatase with substrate spe-
cificity for phosphorylated ERK. In elderly individuals, si-
lencing of DUSP6 increased the expression of T cell
activation markers, such as CD69 and CD25, IL-2 produc-
tion as well as proliferative response [16]. Inhibition of
DUSP6 could be a potential intervention to increase CD4+
TCR-sensitivity by enhancing ERK phosphorylation in
ESRD patients. BCI (an inhibitor of DUSP6 and 1) en-
hanced TCR-induced pERK in CD4+ T cells from elderly
HI, young and elderly ESRD patients, but not young HI,
implying a role for DUSP6 and/or DUSP1 in regulation of
ERK phosphorylation. Based on the age- as well as
differentiation-related expression of DUSP6, but not
DUSP1, in our HI, a potential role for DUSP6 may be
present in defective TCR-induced ERK phosphorylation,
especially in elderly HI and young patients. This needs to
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be confirmed in a larger cohort. Furthermore, use of
siRNA specific for DUSP6 is required to draw a more def-
inite conclusion with respect to the role of DUSP6 in de-
fective TCR-induced phosphorylation of ERK in ESRD
patients. The lack of age-related effects on pERK in CD8+
T cells of ESRD patients and HI, the latter confirming ob-
servations done by another study [16], as well as absence
of effects of BCI on pERK levels in CD8+ T cells, indicates
a different role for DUSP6 in CD8+ T cells compared to
CD4+ T cells. We did not observe an association between
DUSP6 expression and ERK phosphorylation in CD4+ T
cells in ESRD patients. This could be due to the small co-
hort size or imply other DUSPs (e.g. 2, 4 or 5) [45–49] or
upstream signaling molecules to contribute to this defect-
ive TCR-induced ERK phosphorylation in ESRD patients.
ERK over-phosphorylation might be as bad as defective
ERK phosphorylation. ERK over-activation from kidney
cells occurs in the physiologic setting in some chronic kid-
ney diseases, such as compensatory kidney hypertrophy
and in pathologic conditions for example glomerular dis-
ease [50]. Increased ERK phosphorylation in T cells predis-
poses for autoimmunity for example rheumatoid arthritis
[43]. Over-expression of DUSP6 is also reported to impair
T-cell function in chronic viral infections such as hepatitis
C virus infection [51]. Therefore, more research is
warranted evaluating inhibition of DUSP in the setting of
defective T-cell mediated immunity in ESRD patients.
We analyzed the effect of latency for CMV as it repre-
sents chronic antigenic stimulation of T cells, but ERK- or
p38-activation of CD4+ or CD8+ T cells was not different
between the CMV-IgG seropositive population and CMV-
IgG seronegative population following CD3/CD28 stimu-
lation. Highly differentiated memory CD4+ and CD8+ T
cells may accumulate in CMV seropositive individuals and
are functional CMV-specific T cells [29, 52, 53]. The re-
sults of our study show that non-specific TCR stimulation
does not identify a defect p38 and ERK signaling associ-
ated with CMV seropositivity. In accordance with the re-
sults of a previous study, uremia is the major determinant
affecting MAPK pathway parameters in ESRD patients
and not RRT [9, 11, 33].
In the present study, we induced phosphorylation of
p38 in T cells via triggering CD3 [54] and CD28 [26].
Lack of CD28 may only partly explain the decreased p38
activation in more differentiated CD4+ T cells. In
addition to that, senescent human CD27−CD28− CD4+
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Fig. 9 Phosphorylation of ERK in CD4+ T cell subsets without and with BCI treatment from healthy individuals (HI) and end stage renal disease
(ESRD) patients. Phosphorylation of ERK for BCI-pretreated or not BCI-pretreated cells is given for different CD4+ T cell subsets: (a) total, (b) naive,
(c) central memory (CM) and (d) effector memory (EM) of HI (young n = 5; elderly n = 5) and ESRD patients (young n = 5; elderly n = 5). Dots and
squares represent young and elderly HI, upward- and downward-facing triangles correspond to young and elderly patients, respectively.
P value: *< 0.05; Data are given as individual values
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T cells lack several essential upstream components in-
cluding ZAP70 and the loss of TCR signaling machinery
in those cells was associated with a defective calcium in-
flux [31], which may indicate the decreased response of
TCR-mediated activation in the more differentiated T
cells. Interestingly, in contrast to the p38 activation
following CD3/CD28 stimulation, baseline levels
(spontaneous phosphorylation) of p38 increased during
T cells differentiation [55]. This might be caused by
DNA damage in these more differentiated T cells and
mediated by TAB1 (MKK-independent molecule), a key
molecule involved in this auto-phosphorylation [31].
Conclusion
We have described for the first time a uremia-mediated
defect in TCR-induced phosphorylation of ERK which
may contribute to the impaired T-cell mediated immune
response in ESRD patients. Inhibition of DUSP6 specific
for pERK can restore defective p-ERK-mediated activa-
tion of CD4+ T cells in ESRD patients.
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Fig. 10 DUSP6 and DUSP1 expression in CD4+ T cell subsets from healthy individuals (HI) and end stage renal disease (ESRD) patients. DUSP6
expression in (a) total, (b) naive and (c) memory CD4+ T cells; (d) Differentiation-associated DUSP6 expression in CD4+ T cells; DUSP1 expression
in (e) total, (f) naive and (g) memory CD4+ T cells; Dots and squares represent young (n = 4) and elderly HI (n = 6), and upward- and downward-
facing triangles correspond to young (n = 4) and elderly (n = 5) patients, respectively. P value: *< 0.05; **< 0.01; ***< 0.001; Data are given as (indi-
vidual values and) medians with interquartile ranges
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